Based on: Multiple Sclerosis — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 51 candidate interventions for multiple sclerosis that are either approved medicines or have at least one registered clinical trial, built on 10 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 17 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Interferon beta-1b (Betaseron, BAY86-5046) — 4 registered trials · investigational · NCT00787657 NCT00963833 NCT01436838
- Rebif® — 2 registered trials · investigational · NCT02064816
- Ocrelizumab — 1 registered trial · approved medicine · NCT03025269
- Ofatumumab — 1 registered trial · approved medicine · NCT04353492
- ACTH — 1 registered trial · investigational · NCT02315872
- Anti-Mullerian hormone (AMH) level — 1 registered trial · investigational · NCT05754593
- cetrizine — 1 registered trial · investigational · NCT04175834
- Dietary supplement intervention Goodphyte IB Defense — 1 registered trial · investigational · NCT07380022
- Dietary supplement intervention Goodphyte Immunity — 1 registered trial · investigational · NCT07380022
- diphenhydramine — 1 registered trial · investigational · NCT04175834
- Disease-Modifying Therapies (DMTs) — 1 registered trial · investigational · NCT06796504
- Early Harvest Extra Virgin Olive Oil — 1 registered trial · investigational · NCT04120675
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in multiple sclerosis and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: BTK, CD52, IL2RA, ITGA4, LINGO1, MBP, MOG, MS4A1, S1PR1, VDR.
Which trials are registered?
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging NCT02511028 · Completed · Phase PHASE1 · started 2015-11-27
- At Home Use of Stimulation Suits for Managing MS Symptoms NCT07202195 · Recruiting · Phase NA · started 2026-03-16
- Study of the Disease Process of Lymphangioleiomyomatosis NCT00001465 · Recruiting · started 1995-12-18
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) NCT03109288 · Recruiting · Phase PHASE1, PHASE2 · started 2017-08-11
- The HIt HArd and hiT Early in Multiple Sclerosis Trial NCT07517185 · Recruiting · Phase PHASE2 · started 2026-09-01
- Role of Genetic Factors in the Development of Lung Disease NCT00001532 · Recruiting · started 1996-09-13
- Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System NCT00794352 · Recruiting · started 2008-10-01
- Study of Skin Tumors in Tuberous Sclerosis NCT00001975 · Recruiting · started 2000-01-26
- Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis NCT06428006 · Active Not Recruiting · Phase PHASE2 · started 2024-07-30
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis NCT07299019 · Recruiting · Phase PHASE3 · started 2026-03-23
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.